Compare · QTRX vs RVTY
QTRX vs RVTY
Side-by-side comparison of Quanterix Corporation (QTRX) and Revvity Inc. (RVTY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both QTRX and RVTY operate in Biotechnology: Laboratory Analytical Instruments (Industrials), so they compete in similar markets.
- RVTY is the larger of the two at $12.29B, about 67.5x QTRX ($182.1M).
- QTRX has been more active in the news (9 items in the past 4 weeks vs 2 for RVTY).
- RVTY has more recent analyst coverage (20 ratings vs 13 for QTRX).
- Company
- Quanterix Corporation
- Revvity Inc.
- Price
- -
- -
- Market cap
- $182.1M
- $12.29B
- 1M return
- +26.06%
- -
- 1Y return
- -25.29%
- -
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2017
- News (4w)
- 9
- 2
- Recent ratings
- 13
- 20
Quanterix Corporation
Quanterix Corporation, a life sciences company, develops and markets digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a sensitive automated multiplex protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection technology in various applications, including direct detection of nucleic acids. It also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company's products include assay kits and other consumables such as reagents. In addition, it offers contract research services, including sample testing, homebrew assay development, and custom development services. The company primarily operates in the areas of neurology, oncology, cardiology, infectious diseases, and inflammation. It sells its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct sales force, support organizations, and distributors or sales agents. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Billerica, Massachusetts.
Latest QTRX
- Chief Technology Officer Miller Michael Francis converted options into 1,558 shares and covered exercise/tax liability with 467 shares, increasing direct ownership by 3% to 36,068 units (SEC Form 4)
- SEC Form 4 filed by Chief Financial Officer Faessler Jason F.
- Quanterix Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Anthem Blue Cross and Blue Shield Establishes Commercial Coverage for LucentAD® Complete; Quanterix to Present New Data Highlighting Multi-Analyte Advantages
- Director Mendel Scott converted options into 8,073 shares, increasing direct ownership by 51% to 24,056 units (SEC Form 4)
- Director Lai Goldman Myla converted options into 8,073 shares, increasing direct ownership by 116% to 15,041 units (SEC Form 4)
- Director Mendel Scott was granted 3,456 shares, increasing direct ownership by 26% to 16,837 units (SEC Form 4)
- Director Donnelly William P was granted 5,472 shares, increasing direct ownership by 4% to 160,305 units (SEC Form 4)
- Chief Technology Officer Miller Michael Francis converted options into 130 shares and covered exercise/tax liability with 39 shares, increasing direct ownership by 0.26% to 34,977 units (SEC Form 4)
- Chief Financial Officer Sriram Vandana covered exercise/tax liability with 548 shares and converted options into 1,833 shares, increasing direct ownership by 4% to 31,283 units (SEC Form 4)
Latest RVTY
- Revvity to Hold Earnings Call on Tuesday, August 4, 2026
- Revvity Expands Signals AI Ecosystem Through Anthropic Claude Integration
- Bernstein resumed coverage on Revvity with a new price target
- SEC Form 11-K filed by Revvity Inc.
- Revvity Launches Signals AI, a Native Agentic Framework for Accelerating Scientific R&D
- Vice President and CAO Gonzales Anita covered exercise/tax liability with 33 shares, decreasing direct ownership by 0.45% to 7,286 units (SEC Form 4) to cover taxes
- Wolfe Research resumed coverage on Revvity
- SEC Form SD filed by Revvity Inc.
- SEC Form 10-Q filed by Revvity Inc.
- Director Klobuchar Michael A was granted 2,280 shares, increasing direct ownership by 45% to 7,368 units (SEC Form 4)